Department of Radiology, University of Cambridge School of Clinical Medicine
Specialty: Ligand Discovery, Ligand-based Targeting of Disease, Molecular Imaging, Radiopharmaceuticals
Dario Neri was born in Rome on 1. May 1963 and grew up in Siena (Italy). He studied Chemistry at the Scuola Normale Superiore of Pisa (Italy) and earned a PhD in Chemistry from the Swiss Federal Institute of Technology (ETH Zürich), under the supervision of Professor Kurt Wüthrich (Nobel Prize Chemistry 2002). After a post-doctoral research internship (1992-1996) at the Cambridge Centre for Protein Engineering, Medical Research Council Centre in Cambridge (UK), under the supervision of Sir Gregory Winter (Nobel Prize Chemistry 2018), he became professor at ETH Zürich in 1996. Dario Neri has been Full Professor of Biomacromolecules at the Department of Chemistry and Applied Biosciences, ETH Zürich. In October 2020, he moved full-time to Philogen (www.philogen.com), a Swiss-Italian Biotech Company which he had co-founded in 1996 and in which he currently serves as Chief Executive Officer and Chief Scientific Officer, while retaining the ETH Professor title.
Dario Neri has published more than 400 articles in peer-review scientific journals. He is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompe’ Biotec Award 2000, of the Mangia d’Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer of the French Medicinal Chemistry Society in 2011, of the Phoenix Prize 2014, of an ERC Advanced Grant in 2015, the 6th World ADC Award in 2019 and the Paul Harris Fellow Award in 2022.
The research activities of the Neri group and of Philogen focus on the the discovery and development of innovative agents for the imaging and therapy of disease, with a special focus on cancer. This work is the fruit of innovation in the construction and screening of encoded combinatorial libraries of unprecedented size and quality (including antibody libraries and DNA-encoded chemical libraries). The activities of the Neri group and of Philogen have led to the generation of promising pharmaceutical agents, which are currently being investigated in Phase III clinical trials in Europe and in the United States.
Since 1996, Dario has trained more than 80 PhD students and has been actively involved in teaching activities both at the undergraduate and graduate level. His classes included Pharmaceutical Immunology, Gene and Protein Technology, Therapeutic Proteins, as well as Tumor Targeting.
Since September 2022, Dario is a Honorary Senior Visiting Fellow at the Department of Radiology, University of Cambridge.
|Laurea in Chimica||Scuola Normale Superiore, Pisa, Italy||1987|
|Ph.D. in Chemistry||ETH Zürich, Zürich, Switzerland||1992|
|Research Fellowship||Medical Research Council Centre, Cambridge, UK||1992-1996|
|Professor||ETH Zürich, Zürich, Switzerland||1996-present|
Dario Neri and his collaborators mainly work on the targeting of disease (especially cancer) using ligands capable of preferential localization at the disease site, helping spare normal tissues. This research activity is generating promising results in several application fields, including:
- The generation of a novel class of PET radiopharmaceuticals for the imaging of various types of cancer
- The generation of a novel class of radiopharmaceuticals, equipped with alpha- or beta-emitters, for the therapy of various types of cancer
- The generation of small molecule-drug conjugates for cancer therapy
- The generation of antibody-cytokine fusion proteins, which can be used as single agents or in combination with other therapeutic modalities (including radiopharmaceuticals)
Last 5 Publications
A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake.
Galbiati A, Zana A, Bocci M, Millul J, Elsayed A, Mock J, Neri D, Cazzamalli S.J Nucl Med. 2022 May 19:jnumed.122.264036. doi: 10.2967/jnumed.122.264036.
Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA.
Backhaus P, Gierse F, Burg MC, Büther F, Asmus I, Dorten P, Cufe J, Roll W, Neri D, Cazzamalli S, Millul J, Mock J, Galbiati A, Zana A, Schäfers KP, Hermann S, Weckesser M, Tio J, Wagner S, Breyholz HJ, Schäfers M.Eur J Nucl Med Mol Imaging. 2022 May;49(6):1822-1832.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C.Blood Adv. 2022 Jun 28;6(12):3684-3696.
Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody.
Nadal L, Peissert F, Elsayed A, Weiss T, Look T, Weller M, Piro G, Carbone C, Tortora G, Matasci M, Favalli N, Corbellari R, Di Nitto C, Prodi E, Libbra C, Galeazzi S, Carotenuto C, Halin C, Puca E, Neri D, De Luca R.J Immunother Cancer. 2022 Sep;10(9):e005282. doi: 10.1136/jitc-2022-005282.
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT, Marquette K, Chang CB, Golas J, Jain S, Lam MH, Guffroy M, Leal M, Falahatpisheh H, Mathur D, Chen T, Kelleher K, Khandke K, Muszynska E, Loganzo F, Rosfjord E, Lucas J, Kan Z, Subramanyam C, O’Donnell C, Neri D, Gerber HP, May C, Sapra P.Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.
Best 5 Publications
Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applications.
Favalli N, Bassi G, Pellegrino C, Millul J, De Luca R, Cazzamalli S, Yang S, Trenner A, Mozaffari NL, Myburgh R, Moroglu M, Conway SJ, Sartori AA, Manz MG, Lerner RA, Vogt PK, Scheuermann J, Neri D.Nat Chem. 2021 Jun;13(6):540-548.
Versatile protein recognition by the encoded display of multiple chemical elements on a constant macrocyclic scaffold.
Li Y, De Luca R, Cazzamalli S, Pretto F, Bajic D, Scheuermann J, Neri D.Nat Chem. 2018 Apr;10(4):441-448.
Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform.
Neri D, Carnemolla B, Nissim A, Leprini A, Querzè G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G.Nat Biotechnol. 1997 Nov;15(12):1271-5.
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis.
Cazzamalli S, Dal Corso A, Widmayer F, Neri D.J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature.
Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D.Nat Biotechnol. 2002 Mar;20(3):264-9